Skip to content

Member Survey: Federal Budget Reforms

Some tax changes proposed in the 2026-27 Federal Budget could have major unintended consequences for Australia's biotech and life sciences sector. We have heard from members that there are three primary areas of concern:
  1. Proposed change to the RDTI to limit access to refundable tax offsets to companies less than 10 years old
  2. Removing eligibility for ‘supporting R&D’ from RDTI claims
  3. Impact to start-up and early-stage company investment and employee share incentives from proposed changes to how capital gains are taxed
AusBiotech is urgently engaging Government on these issues and needs your voice. To inform our advocacy, we are seeking sector feedback via this short survey. It will take less than 5 minutes to complete. Please respond by Friday 5 June.

Your input is essential to building the strongest possible case for change.
1.Name(Required.)
2.Email(Required.)
3.What is the name of your company?(Required.)
4.What postcode is your company based in?(Required.)
5.Which best describes your organisation?(Required.)
6.How many years has your company been operational?(Required.)
7.What stage of R&D or clinical development is your lead program currently in?(Required.)
8.Do you currently access the refundable R&D Tax Incentive?(Required.)
9.If the refundable RDTI were limited to companies under 10 years old, what impact would this have to your organisation?(Required.)
10.If yes, what would be the likely impact?
(Provide a brief explanation. If possible, please quantify the impact in terms of e.g. job losses/ patients affected).
11.The Federal Budget proposes removing eligibility of ‘supporting R&D’ activities from the RDTI to enable a higher offset rate to be applied to ‘core activities’. Will this proposed change adversely affect your business?(Required.)
12.If yes, what would be the likely impact?
(Provide a brief explanation of the impact on your organisation and/or those with whom you work.)
13.Will the proposed capital gains tax changes (i.e., replacing the 50% discount on capital gains with cost-base indexation) impact your business?(Required.)
14.If yes, what would be the likely impact?
(Provide a brief explanation.)
15.Are there any other comments you would like to make?
16.Are you willing for AusBiotech to contact you for a case study or further evidence?(Required.)
17.May AusBiotech use your de-identified responses in advocacy, media and policy submissions?(Required.)